New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

By |2024-05-13T12:11:44+01:00May 10th, 2024|News|

New tiopronin delayed-release tablets launch with patient support for the treatment of cystinuria in the US

By |2024-05-13T12:11:20+01:00May 7th, 2024|News|

Cycle Pharmaceuticals and Inceptua Group Partner for a Free Goods Programme for Patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU)

By |2024-05-03T12:00:10+01:00January 15th, 2024|News|

New drug, TASCENSO ODT® (fingolimod), launched to meet the needs of multiple sclerosis patients in the US left without essential patient support

By |2023-02-13T10:54:43+00:00February 13th, 2023|News|

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT® (fingolimod)

By |2023-01-13T11:37:55+00:00January 16th, 2023|News|

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023

By |2022-11-30T11:21:25+00:00November 1st, 2022|News|

Tony Cates joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:31:47+00:00October 6th, 2021|News, Nityr|

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

By |2022-11-30T11:32:04+00:00September 28th, 2021|News, Nityr|

Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

By |2022-11-30T11:32:18+00:00September 10th, 2021|News, Nityr|

Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer

By |2021-06-28T11:44:17+01:00June 28th, 2021|Corporate, News|